参考文献/References:
[1].DeLalio LJ,Sved AF,Stocker SD. Sympathetic nervous system contributions to hypertension:updates and therapeutic relevance[J]. Can J Cardiol,2020,36(5):712-720.
[2].Grassi G,Mark A,Esler M. The sympathetic nervous system alterations in human hypertension[J]. Circ Res,2015,116(6):976-990.
[3].Kasprzycki K,Petkow-Dimitrow P,Krawczyk-O?óg A,et al. Anatomic variations of renal arteries as an important factor in the effectiveness of renal denervation in resistant hypertension[J].?J Cardiovasc Dev Dis,2023,10(9):371.
[4].Krum H,Schlaich M,Whitbourn R,et al. Catheter-based renal sympathetic denervation for resistant hypertension:a multicentre safety and proof-of-principle cohort study[J]. Lancet,2009,373(9671):1275-1281.
[5].Hoogerwaard AF,Elvan A. Is renal denervation still a treatment option in cardiovascular disease?[J]. Trends Cardiovasc Med,2020,30(4):189-195.
[6].Johns EJ,Kopp UC,DiBona GF. Neural control of renal function[J]. Compr Physiol,2011,1(2):731-767.
[7].王辉,段大为,刘迎午. 经皮去肾交感神经消融术治疗顽固性高血压的研究进展[J]. 生物医学工程与临床,2021,25(1):117-121.
[8].Sobotka PA,Mahfoud F,Schlaich MP,et al. Sympatho-renal axis in chronic disease[J]. Clin Res Cardiol,2011,100(12):1049-1057.
[9].Drexel T,Bertog SC,Vaskelyte L,et al. Renal denervation[J]. Anadolu Kardiyol Derg,2014,14(2):186-191.
[10].Floras JS. Sympathetic nervous system activation in human heart failure:clinical implications of an updated model[J]. J Am Coll Cardiol,2009,54(5):375-385.
[11].Arimoto T,Tada H,Igarashi M,et al. High washout rate of iodine-123-metaiodobenzylguanidine imaging predicts the outcome of catheter ablation of atrial fibrillation[J]. J Cardiovasc Electrophysiol,2011,22(12):1297-1304.
[12].Esler M,Lambert G,Jennings G. Regional norepinephrine turnover in human hypertension[J]. Clin Exp Hypertens A,1989,11(suppl 1):75-89.
[13].Kario K,Hettrick DA,Prejbisz A,et al. Obstructive sleep apnea-induced neurogenic nocturnal hypertension:a potential role of renal denervation?[J]. Hypertension,2021,77(4):1047-1060.
[14].Mancia G,Bousquet P,Elghozi JL,et al. The sympathetic nervous system and the metabolic syndrome[J]. J Hypertens,2007,25(5):909-920.
[15].Hausberg M,Grassi G. Mechanisms of sympathetic overactivity in patients with chronic renal failure:a role for chemoreflex activation?[J]. J Hypertens,2007,25(1):47-49.
[16].Esler MD,Krum H,Sobotka PA,et al. Renal sympathetic denervation in patients with treatment-resistant hypertension(The Symplicity HTN-2 Trial):a randomised controlled trial[J]. Lancet,2010,376(9756):1903-1909.
[17].Parati G,Esler M. The human sympathetic nervous system:its relevance in hypertension and heart failure[J]. Eur Heart J,2012,33(9):1058-1066.
[18].Yu L,Huang B,Wang Z,et al. Impacts of renal sympathetic activation on atrial fibrillation:the potential role of the autonomic cross talk between kidney and heart[J]. J Am Heart Assoc,2017,6(3):e004716.
[19].Goyal A,Jain H,Verma A,et al. The role of renal denervation in cardiology and beyond:an updated comprehensive review and future directives[J]. Curr Probl Cardiol,2024,49(2):102196.
[20].Cao F,Gao YX,Wang Y. Research advance of renin-angiotensin-aldosterone system in atrial fibrillation and atrial structural remodeling[J]. Adv Cardiovasc Dis,2018,39(4):528-531.
[21].Ukena C,Bauer A,Mahfoud F,et al. Renal sympathetic denervation for treatment of electrical storm:first-in-man experience[J]. Clin Res Cardiol,2012,101(1):63-67.
[22].Pokushalov E,Romanov A,Corbucci G,et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension[J]. J Am Coll Cardiol,2012,60(13):1163-1170.
[23].Vollmann D, Sossalla S, Schroeter M R, et al. Renal artery ablation instead of pulmonary vein ablation in a hypertensive patient with symptomatic, drug-resistant, persistent atrial fibrillation[J]. Clinical Research in Cardiology, 2013: 1-4.
[24].余静. 肾动脉交感神经消融有望成为一种新的治疗心力衰竭的方法[J]. 兰州大学学报(医学版),2022,48(2):1-3.
[25].张艳,包明威. 干预交感神经过度激活治疗心力衰竭的研究进展[J]. 医学研究杂志,2022,51(12):14-17,21.
[26].Sharp TE 3rd,Lefer DJ. Renal denervation to treat heart failure[J]. Annu Rev Physiol,2021,83:39-58.
[27].McDonagh TA,Metra M,Adamo M,et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC). With the special contribution of the Heart Failure Association(HFA) of the ESC[J]. Eur J Heart Fail,2022,24(1):4-131.
[28].Polhemus DJ,Trivedi RK,Gao J,et al. Renal sympathetic denervation protects the failing heart via inhibition of neprilysin activity in the kidney[J]. J Am Coll Cardiol,2017,70(17):2139-2153.
[29].Jaén-?guila F,Vargas-Hitos JA,Mediavilla-García JD. Implications of renal denervation therapy in patients with sleep apnea[J]. Int J Hypertens,2015,2015:408574.
[30].Davies JE,Manisty CH,Petraco R,et al. First-in-man safety evaluation of renal denervation for chronic systolic heart failure:primary outcome from REACH-Pilot study[J]. Int J Cardiol,2013,162(3):189-192.
[31].国家卫生健康委高血压诊疗研究重点实验室学术委员会,国家卫生健康委高血压诊疗研究重点实验室,新疆维吾尔自治区人民医院高血压中心. 2023阻塞性睡眠呼吸暂停相关性高血压临床诊断和治疗专家共识[J]. 中华高血压杂志,2023,31(12):1142-1155.
[32].Shantha GP,Pancholy SB. Effect of renal sympathetic denervation on apnea-hypopnea index in patients with obstructive sleep apnea:a systematic review and meta-analysis[J]. Sleep Breath,2015,19(1):29-34.
[33].Flaa A,Aksnes TA,Kjeldsen SE,et al. Increased sympathetic reactivity may predict insulin resistance:an 18-year follow-up study[J]. Metabolism,2008,57(10):1422-1427.
[34].Oliveira TL,Lincevicius GS,Shimoura CG,et al. Effects of renal denervation on cardiovascular,metabolic and renal functions in streptozotocin-induced diabetic rats[J]. Life Sci,2021,278:119534.
[35].Santulli G,Trimarco B,Iaccarino G. G-protein-coupled receptor kinase 2 and hypertension:molecular insights and pathophysiological mechanisms[J]. High Blood Press Cardiovasc Prev,2013,20(1):5-12.
[36].Mahfoud F,Schlaich M,Kindermann I,et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension:a pilot study[J]. Circulation,2011,123(18):1940-1946.
[37].Manukyan M,Falkovskaya A,Mordovin V,et al. Favorable effect of renal denervation on elevated renal vascular resistance in patients with resistant hypertension and type 2 diabetes mellitus[J]. Front Cardiovasc Med,2022,9:1010546.
[38].Veiga AC,Milanez MIO,Ferreira GR,et al. Selective afferent renal denervation mitigates renal and splanchnic sympathetic nerve overactivity and renal function in chronic kidney disease-induced hypertension[J]. J Hypertens,2020,38(4):765-773.
[39].Lv J,Ehteshami P,Sarnak MJ,et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease:a systematic review and meta-analysis[J]. CMAJ,2013,185(11):949-957.
[40].Hering D,Marusic P,Duval J,et al. Effect of renal denervation on kidney function in patients with chronic kidney disease[J]. Int J Cardiol,2017,232:93-97.
[41].Solbu MD,Miroslawska A,Norvik JV,et al. Kidney function and markers of renal damage after renal denervation. Does method of measurement matter? The Reshape CV-Risk Study[J]. J Clin Hypertens(Greenwich),2021,23(5):954-962.
[42].Liu S,Bian R,Qian Y,et al. Catheter-based renal denervation in Chinese patients with chronic kidney disease and uncontrolled hypertension[J]. J Clin Hypertens(Greenwich),2023,25(1):71-77.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(3):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(3):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(3):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(3):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(3):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(3):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(3):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(3):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(3):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]